Preparation of murine B7.1-glycosylphosphatidylinositol and transmembrane-anchored staphylococcal enterotoxin: A dual-anchored tumor cell vaccine and its antitumor effect

Cancer

Volumn 103, Issue 7, 2005, Pages 1519-1528

  Yi, Pingyong ^a   Yu, Hai ^a   Ma, Wenxue ^b   Wang, Qingqing ^a   Minev, Boris R ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immunotherapy; Murine B7.1; Protein transfer; Staphylococcal enterotoxin A; Tumor vaccine

Indexed keywords

CYTOKINE; DNA; GAMMA INTERFERON; GLYCOSYLPHOSPHATIDYLINOSITOL; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2; MITOMYCIN C; STAPHYLOCOCCUS ENTEROTOXIN A; SUPERANTIGEN; TUMOR VACCINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONFOCAL MICROSCOPY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PURIFICATION; TUMOR CELL; TUMOR GROWTH; TUMOR MODEL; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD80; CANCER VACCINES; CELL MEMBRANE; CYTOTOXICITY, IMMUNOLOGIC; ENTEROTOXINS; FEASIBILITY STUDIES; FEMALE; GLYCOSYLPHOSPHATIDYLINOSITOLS; LYMPHOCYTE ACTIVATION; LYMPHOMA; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; RANDOM ALLOCATION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 15744401625     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20943     Document Type: Article

References (34)

1. Qin Z, Richter G, Schuler T, et al. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med. 1998;4:627-630.
2. Miescher S, Whiteside TL, Moretta L, et al. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol. 1987;138:4004-4011.
3. Restifo NP, Esquivel F, Kawakami Y, et al. Identification of human cancers deficient in antigen processing. J Exp Med. 1993;177:265-272.
4. Seliger B, Maeurer MJ, Ferrone S. TAP off-tumors on. Immunol Today. 1997;18:292-299.
5. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992;71:1093-1102.
6. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 1993;259:368-370.
7. Ostrand-Rosenberg S, Clements VK, Thakur A, et al. Transfection of major histocompatibility complex class I and class II genes causes tumour rejection. J Immunogenet. 1989;16:343-349.
8. Hodge JW, Abrams S, Schlom J, et al. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res. 1994;54:5552-5555.
9. Tykocinski ML, Kaplan DR, Medof ME. Antigen-presenting cell engineering. The molecular toolbox. Am J Pathol. 1996;148:1-16.
10. Medof ME, Nagarajan S, Tykocinski ML. Cell-surface engineering with GPI-anchored proteins. FASEB J. 1996;10:574-586.
11. Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med. 1984;160:1558-1578.
12. McHugh RS, Ahmed SN, Wang YC, et al. Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci USA. 1995;92:8059-8063.
13. Ma W, Yu H, Wang Q, et al. In vitro biological activities of transmembrane superantigen staphylococcal enterotoxin A fusion protein. Cancer Immunol Immunother. 2004;53:118-124.
14. Pulaski BA, Terman DS, Khan S, et al. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res. 2000;60:2710-2715.
15. Coughlin CM, Wysocka M, Kurzawa HL, et al. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res. 1995;55:4980-4987.
16. Mazzocchi A, Melani C, Rivoltini L, et al. Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes. Cancer Immunol Immunother. 2001;50:199-211.
17. Ma W, Yu H, Wang Q, et al. A novel approach for cancer immunotherapy: tumor cells with anchored superantigen SEA generate effective antitumor immunity. J Clin Immunol. 2004;24:294-301.
18. Freeman GJ, Gray GS, Gimmi CD, et al. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med. 1991;174:625-631.
19. Millan JL. Molecular cloning and sequence analysis of human placental alkaline phosphatase. J Biol Chem. 1986;261:3112-3115.
20. Horton RM, Hunt HD, Ho SN, et al. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene. 1989;77:61-68.
21. Betley MJ, Mekalanos JJ. Nucleotide sequence of the type A staphylococcal enterotoxin gene. J Bacteriol. 1988;170:34-41.
22. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230:1132-1139.
23. Vistica DT, Skehan P, Scudiero D, et al. Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res. 1991;51:2515-2520.
24. Papageorgiou AC, Acharya KR. Superantigens as immunomodulators: recent structural insights. Structure. 1997;5:991-996.
25. Kotb M. Superantigens of gram-positive bacteria: structure-function analyses and their implications for biological activity. Curr Opin Microbiol. 1998;1:56-65.
26. Dohlsten M, Abrahmsen L, Bjork P, et al. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy. Proc Natl Acad Sci USA. 1994;91:8945-8949.
27. Sakurai N, Kudo T, Suzuki M, et al. SEA-scFv as a bifunctional antibody: construction of a bacterial expression system and its functional analysis. Biochem Biophys Res Commun. 1999;256:223-230.
28. Shrayer DP, Kouttab N, Hearing VJ, et al. Immunization of mice with melanoma cells transfected to secrete the superantigen, staphylococcal enterotoxin A. Cancer Immunol Immunother. 1998;46:7-13.
29. Rosendahl A, Kristensson K, Carlsson M, et al. Long-term survival and complete cures of B16 melanoma-carrying animals after therapy with tumor-targeted IL-2 and SEA. Int J Cancer. 1999;81:156-163.
30. Renno T, Hahne M, Tschopp J, et al. Peripheral T cells undergoing superantigen-induced apoptosis in vivo express B220 and upregulate Fas and Fas ligand. J Exp Med. 1996;183:431-437.
31. Wang Q, Yu H, Zhang L, et al. Adenovirus-mediated intra-tumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer. J Mol Med. 2002;80:585-594.
32. Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity. 1995;3:87-98.
33. Tatsumi T, Takehara T, Katayama K, et al. Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma. Hepatology. 1997;25:1108-1114.
34. Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med. 1994;179:523-532.